Abliva AB
Abliva - Delivering mitochondrial healthAbliva discovers and develops medicines for the treatment of mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is in clinical trials. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
- 2:16
- 9 ай бұрын
Abliva - Designing Therapies for Mitochondrial Disease - World Mitochondrial Disease Week 2023
- 0:28
- 9 ай бұрын
Abliva - World Mitochondrial Disease Week 2023
- 3:46
- 10 ай бұрын
Abliva - Primary Mitochondrial Disease and NAD+/NADH
- 2:16
- 10 ай бұрын
Abliva - About Lead Candidate KL1333
- 3:47
- Жыл бұрын
Abliva - A Patient-Centric Approach to Drug Development - World Mitochondrial Disease Week 2022
- 3:43
- Жыл бұрын
Abliva - Abliva’s upcoming Phase 2/3 study with KL1333 - World Mitochondrial Disease Week 2022
- 9:35
- Жыл бұрын
Abliva - Living with Mitochondrial Disease: full interview - World Mitochondrial Disease Week 2022
- 2:32
- Жыл бұрын
Abliva - Introducing Mitochondrial “Mito” Disease - World Mitochondrial Disease Week 2022
- 0:28
- Жыл бұрын
Abliva is preparing for this year's World Mitochondrial Disease Week - 18 -24 September 2022
- 2:30
- 2 жыл бұрын
Abliva - KL1333 and the upcoming Phase 2/3-study
- 3:41
- 2 жыл бұрын
Abliva - Drug Development - Mito Disease
- 2:51
- 2 жыл бұрын
Abliva - Living with Mito Disease
- 3:39
- 2 жыл бұрын
Abliva - Designing Therapies for Mito Disease
- 2:36
- 2 жыл бұрын
Abliva - Introducing Mitochondrial “Mito” Disease
- 5:29
- 2 жыл бұрын
KL1333 (Abliva drug candidate) e-poster pres, Dr. Pitceathly, UMDF Mitochondrial Medicine 2021
- 8:25
- 3 жыл бұрын
CEO comment from Abliva's Annual General Meeting 2021
- 2:23
- 3 жыл бұрын
Abliva's CMO Magnus Hansson presents poster lightning talk at Mitochondrial Medicine 2020
- 16:02
- 3 жыл бұрын
Interview: Frank J. Sasinowski, US Consultant specializing in regulatory matters for orphan drugs
- 10:24
- 3 жыл бұрын
Interview with Elja van der Veer, Founder and Chair of International Mito Patients (IMP)
- 1:49:40
- 3 жыл бұрын
Пікірлер